Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

SpringWorks Therapeutics, Inc. (SWTX)

24.98   -1.04 (-4%) 03-24 12:20
Open: 25.96 Pre. Close: 26.02
High: 26.135 Low: 24.9
Volume: 112,456 Market Cap: 1,561(M)

Technical analysis

as of: 2023-03-24 12:04:39 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 34.97     One year: 38.54
Support: Support1: 25    Support2: 20.8
Resistance: Resistance1: 29.94    Resistance2: 33
Pivot: 29.23
Moving Average: MA(5): 26.66     MA(20): 29.61
MA(100): 27.14     MA(250): 29.86
MACD: MACD(12,26): -1     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 3.8     %D(3): 8.2
RSI: RSI(14): 33.7
52-week: High: 62.4  Low: 13.6
Average Vol(K): 3-Month: 727 (K)  10-Days: 878 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ SWTX ] has closed above bottom band by 3.7%. Bollinger Bands are 91.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 27.72 - 27.94 27.94 - 28.09
Low: 25.17 - 25.4 25.4 - 25.56
Close: 25.71 - 26.08 26.08 - 26.32

Company Description

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Headline News

Mon, 20 Mar 2023
Peregrine Capital Management LLC Purchases New Position in ... - MarketBeat

Tue, 14 Mar 2023
Trexquant Investment LP Decreases Position in SpringWorks ... - MarketBeat

Sun, 12 Mar 2023
Quantamental Technologies LLC acquires 8,011 SpringWorks ... - Best Stocks

Wed, 08 Mar 2023
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors - Yahoo Finance

Tue, 28 Feb 2023
Springworks Therapeutics Inc Up 4.13% To $31.75 After Earnings Beat - InvestorsObserver

Tue, 28 Feb 2023
SpringWorks Therapeutics: Q4 Earnings Snapshot - mySA

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 62 (M)
Shares Float 38 (M)
% Held by Insiders 7.5 (%)
% Held by Institutions 103.8 (%)
Shares Short 12,480 (K)
Shares Short P.Month 10,370 (K)

Stock Financials

EPS -2.22
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.59
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -27.5
Return on Equity (ttm) -48.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.13
Qtrly Earnings Growth 0
Operating Cash Flow -154 (M)
Levered Free Cash Flow -83 (M)

Stock Valuations

PE Ratio -11.37
PEG Ratio 0
Price to Book value 2.61
Price to Sales 0
Price to Cash Flow -10.2

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.